Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

Clinical trial NCT05797233 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05797233
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia B-Cell Chronic Lymphocytic Leukemia Lymphoma, B-Cell

Start date: 2023-08-28
Primary completion: 2028-12-30
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.